SEL 212
Alternative Names: Non-immunogenic uricase; Pegadricase-SVP; Pegsiticase-SVP; SEL-037/SEL-110; SEL-212; SEL-212A; SEL-212B; SVP-Rapamycin/pegsiticaseLatest Information Update: 09 Jul 2024
At a glance
- Originator Selecta Biosciences
- Developer Cartesian Therapeutics
- Class Antigouts; Enzymes; Oxidoreductases; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Urate oxidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Gout
Most Recent Events
- 02 Jul 2024 Preregistration for Gout (Combination therapy, Treatment-experienced) in USA (IV)
- 31 Mar 2024 SEL 212 receives fast track designation for Gout in USA
- 10 Nov 2023 Pooled analysis of adverse events and efficacy data from a phase III DISSOLVE trials in Gout presented at the ACR convergence 2023 (ACR-2023)